Revisiting Hereditary Hemochromatosis: Current Concepts and Progress

American Journal of Medicine

Volumn 119, Issue 5, 2006, Pages 391-399

  Yen, Andrew W ^a   Fancher, Tonya L ^a   Bowlus, Christopher L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C282Y; Hemochromatosis; HFE; Iron overload

Indexed keywords

DEFEROXAMINE; IRON;

ARTHROPATHY; CHRONIC LIVER DISEASE; CLINICAL FEATURE; COMORBIDITY; DIAGNOSTIC APPROACH ROUTE; FATTY LIVER; FERRITIN BLOOD LEVEL; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HOMOZYGOSITY; HUMAN; HYPERPIGMENTATION; IRON METABOLISM; IRON OVERLOAD; PATHOPHYSIOLOGY; PHLEBOTOMY; PORTOCAVAL SHUNT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SIDEROBLASTIC ANEMIA; THALASSEMIA;

DIAGNOSIS, DIFFERENTIAL; EPIDEMIOLOGIC STUDIES; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INCIDENCE; IRON OVERLOAD; MASS SCREENING; MEMBRANE PROTEINS; PROGNOSIS;

EID: 33646153508     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.10.041     Document Type: Review

References (60)

1. Distante S., Robson K.J., Graham-Campbell J., Arnaiz-Villena A., Brissot P., and Worwood M. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet 115 4 (2004) 269-279
2. Lucotte G., and Dieterlen F. A European allele map of the C282Y mutation of hemochromatosis. Celtic versus Viking origin of the mutation?. Blood Cells Mol Dis 31 2 (2003) 262-267
3. Feder J.N., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13 4 (1996) 399-408
4. Nielsen P., Carpinteiro S., Fischer R., Cabeda J.M., Porto G., and Gabbe E.E. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. Br J Haematol 103 3 (1998) 842-845
5. Waalen J., Felitti V., Gelbart T., Ho N.J., and Beutler E. Penetrance of hemochromatosis. Blood Cells Mol Dis 29 3 (2002) 418-432
6. Waalen J., Nordestgaard B.G., and Beutler E. The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol 18 2 (2005) 203-220
7. Andrews N.C. Disorders of iron metabolism. N Engl J Med 341 26 (1999) 1986-1995
8. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 350 23 (2004) 2383-2397
9. Stuart K.A., Anderson G.J., Frazer D.M., et al. Duodenal expression of iron transport molecules in untreated haemochromatosis subjects. Gut 52 7 (2003) 953-959
10. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102 3 (2003) 783-788
11. Nicolas G., Viatte L., Lou D.Q., et al. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 34 1 (2003) 97-101
12. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroprotein and inducing its internalization. Science 306 5704 (2004) 2090-2093
13. Beutler E., Gelbart T., West C., et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 22 2 (1996) 187-194 discussion 194a-194b
14. Carella M., D'Ambrosio L., Totaro A., et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet 60 4 (1997) 828-832
15. Jazwinska E.C., Cullen L.M., Busfield F., et al. Haemochromatosis and HLA-H. Nat Genet 14 3 (1996) 249-251
16. Jouanolle A.M., Gandon G., Jezequel P., et al. Haemochromatosis and HLA-H. Nat Genet 14 3 (1996) 251-252
17. Medicine M-NIfG: Hemochromatosis: Online Mendelian Inheritance in Man (OMIM) (2000). http://www.nslij-genetics.org/omim.html Available at http://www.nslij-genetics.org/omim.html
18. Moalem S., Weinberg E.D., and Percy M.E. Hemochromatosis and the enigma of misplaced iron. implications for infectious disease and survival. Biometals 17 2 (2004) 135-139
19. Steinberg K.K., Cogswell M.E., Chang J.C., et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 285 17 (2001) 2216-2222
20. Adams P.C., Reboussin D.M., Barton J.C., et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352 17 (2005) 1769-1778
21. McDonnell S.M., Preston B.L., Jewell S.A., et al. A survey of 2,851 patients with hemochromatosis. symptoms and response to treatment. Am J Med 106 6 (1999) 619-624
22. Niederau C., Strohmeyer G., and Stremmel W. Epidemiology, clinical spectrum and prognosis of hemochromatosis. Adv Exp Med Biol 356 (1994) 293-302
23. Adams P.C., Kertesz A.E., and Valberg L.S. Clinical presentation of hemochromatosis. a changing scene. Am J Med 90 4 (1991) 445-449
24. Adams P.C., Deugnier Y., Moirand R., and Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 25 1 (1997) 162-166
25. Fracanzani A.L., Fargion S., Romano R., et al. Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology 22 4 Pt 1 (1995) 1127-1131
26. Franchini M., and Veneri D. Recent advances in hereditary hemochromatosis. Ann Hematol 84 6 (2005) 347-352
27. Niederau C., Fischer R., Purschel A., Stremmel W., Haussinger D., and Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110 4 (1996) 1107-1119
28. Crawford D.H., Fletcher L.M., Hubscher S.G., et al. Patient and graft survival after liver transplantation for hereditary hemochromatosis. implications for pathogenesis. Hepatology 39 6 (2004) 1655-1662
29. Elmberg M., Hultcrantz R., Ekbom A., et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 125 6 (2003) 1733-1741
30. Bruix J., Sherman M., Llovet J.M., et al., European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35 3 (2001) 421-430
31. Rivers J., Garrahy P., Robinson W., and Murphy A. Reversible cardiac dysfunction in hemochromatosis. Am Heart J 113 1 (1987) 216-217
32. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1994. A 25-year-old man with the recent onset of diabetes mellitus and congestive heart failure. N Engl J Med 331 7 (1994) 460-446
33. Nielsen P., Fischer R., Buggisch P., and Janka-Schaub G. Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Br J Haematol 123 5 (2003) 952-953
34. Tavill A.S. Diagnosis and management of hemochromatosis. Hepatology 33 5 (2001) 1321-1328
35. Nelson R.L., Baldus W.P., Rubenstein A.H., Go V.L., and Service F.J. Pancreatic alpha-cell function in diabetic hemochromatotic subjects. J Clin Endocrinol Metab 49 3 (1979) 412-416
36. Hramiak I.M., Finegood D.T., and Adams P.C. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med 20 2 (1997) 110-118
37. Jiang R., Manson J.E., Meigs J.B., Ma J., Rifai N., and Hu F.B. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291 6 (2004) 711-717
38. Iyer R., Duckworth W.C., and Solomon S.S. Hypogonadism in idiopathic hemochromatosis. Endocrine studies. Arch Intern Med 141 4 (1981) 517-518
39. Kelly T.M., Edwards C.Q., Meikle A.W., and Kushner J.P. Hypogonadism in hemochromatosis. reversal with iron depletion. Ann Intern Med 101 5 (1984) 629-632
40. Edwards C.Q., Kelly T.M., Ellwein G., and Kushner J.P. Thyroid disease in hemochromatosis. Increased incidence in homozygous men. Arch Intern Med 143 10 (1983) 1890-1893
41. Jordan J.M. Arthritis in hemochromatosis or iron storage disease. Curr Opin Rheumatol 16 1 (2004) 62-66
42. Gochee P.A., and Powell L.W. What's new in hemochromatosis. Curr Opin Hematol 8 2 (2001) 98-104
43. Wang X.S., Lee S., Simmons Z., et al. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci 227 1 (2004) 27-33
44. Mehrany K., Drage L.A., Brandhagen D.J., and Pittelkow M.R. Association of porphyria cutanea tarda with hereditary hemochromatosis. J Am Acad Dermatol 51 2 (2004) 205-211
45. Olynyk J.K., Cullen D.J., Aquilia S., Rossi E., Summerville L., and Powell L.W. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 341 10 (1999) 718-724
46. Edwards C.Q., Griffen L.M., Goldgar D., Drummond C., Skolnick M.H., and Kushner J.P. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 318 21 (1988) 1355-1362
47. Beutler E., Felitti V., Gelbart T., and Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 133 5 (2000) 329-337
48. Schmitt B., Golub R.M., and Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level. systematic review for the American College of Physicians. Ann Intern Med 143 7 (2005) 522-536
49. Dooley J.S. Diagnosis and management of genetic haemochromatosis. Best Pract Res Clin Haematol 15 2 (2002) 277-293
50. Edwards C.Q., and Kushner J.P. Screening for hemochromatosis. N Engl J Med 328 22 (1993) 1616-1620
51. Morrison E.D., Brandhagen D.J., Phatak P.D., et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 138 8 (2003) 627-633
52. Olynyk J.K., St Pierre T.G., Britton R.S., Brunt E.M., and Bacon B.R. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis. a new role for magnetic resonance imaging. Am J Gastroenterol 100 4 (2005) 837-841
53. Qaseem A., Aronson M., Fitterman N., Snow V., Weiss K.B., and Owens D.K. Screening for hereditary hemochromatosis. a clinical practice guideline from the American College of Physicians. Ann Intern Med 143 7 (2005) 517-521
54. Olynyk J.K., Hagan S.E., Cullen D.J., Beilby J., and Whittall D.E. Evolution of untreated hereditary hemochromatosis in the Busselton population. a 17-year study. Mayo Clin Proc 79 3 (2004) 309-313
55. Andersen R.V., Tybjaerg-Hansen A., Appleyard M., Birgens H., and Nordestgaard B.G. Hemochromatosis mutations in the general population. iron overload progression rate. Blood 103 8 (2004) 2914-2919
56. Delatycki M.B., Powell L.W., and Allen K.J. Hereditary hemochromatosis genetic testing of at-risk children. what is the appropriate age?. Genet Test 8 2 (2004) 98-103
57. Hover A.R., McDonnell S.M., and Burke W. Changing the clinical management of hereditary hemochromatosis. translating screening and early case detection strategies into clinical practice. Arch Intern Med 164 9 (2004) 957-961
58. Barton J.C., McDonnell S.M., Adams P.C., et al., Hemochromatosis Management Working Group. Management of hemochromatosis. Ann Intern Med 129 11 (1998) 932-939
59. Hicken B.L., Tucker D.C., and Barton J.C. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 98 9 (2003) 2072-2077
60. Leitman S.F., Browning J.N., Yau Y.Y., et al. Hemochromatosis subjects as allogeneic blood donors. a prospective study. Transfusion 43 11 (2003) 1538-1544